Keyphrases
Uveitis
100%
Age-related Macular Degeneration
68%
Visual Acuity
55%
Retinal pigment Epithelium
37%
Visual Outcome
27%
Randomized Controlled Trial
27%
Bevacizumab
26%
Clinical Manifestations
21%
After Surgery
21%
Behet's Disease
18%
Optical Coherence Tomography Angiography (OCT-A)
17%
Best-corrected Visual Acuity
17%
Birdshot
17%
ERAP2
17%
Retinal Angiomatous Proliferation
17%
Tuberculosis
17%
Adalimumab
17%
Ophthalmologist
17%
Central Serous Chorioretinopathy
17%
Bevacizumab Treatment
15%
Treatment Strategy
13%
Intraocular Lymphoma
12%
Ocular Inflammation
12%
Neovascular Age-related Macular Degeneration (nAMD)
12%
B Cells
12%
Fluorescein Angiography
12%
Odds Ratio
12%
Photodynamic Therapy
11%
Sarcoidosis
11%
Quality of Life
10%
Primary Vitreoretinal Lymphoma
10%
HLA-A29
10%
Scleritis
10%
Clinical Characteristics
9%
Pathogenic Variants
9%
Multisystem
9%
Indocyanine Green Angiography
9%
Central Foveal Thickness
9%
Flow Cytometric Immunophenotyping
8%
Multicolor
8%
Intravitreal anti-VEGF
8%
Utility Value
8%
ROSAH Syndrome
8%
Joint Model
8%
Dynamic Prediction
8%
SF-6D
8%
State-based
8%
ALPK1
8%
Autosomal Dominant Disorder
8%
Uveitis Etiology
8%
Medicine and Dentistry
Retinal Pigment Epithelium
40%
Uveitis
38%
Choroid
34%
Visual Acuity
33%
Disease
26%
Age Related Macular Degeneration
25%
Optical Coherence Tomography Angiography
20%
Optical Coherence Tomography
18%
Central Serous Retinopathy
17%
Best Corrected Visual Acuity
15%
Sarcoidosis
14%
Photodynamic Therapy
13%
Fluorescein Angiography
12%
Blood Flow
12%
Iris
10%
Odds Ratio
10%
Recurrent Disease
10%
Angiography
10%
Visual Pigment
10%
Indocyanine Green Angiography
9%
Vasculotropin
9%
Central Nervous System
9%
Tumor Necrosis Factor
9%
Systemic Disease
8%
Fibroblast
8%
Autosomal Dominant Disorder
8%
Revascularization
8%
Autosomal Dominant Inheritance
8%
Optic Nerve
8%
Intraocular Lymphoma
8%
Immunophenotyping
8%
Somatostatin
8%
Central Retinal Vein Occlusion
8%
Tissue Plasminogen Activator
8%
Fc Receptor
8%
Octreotide
8%
Scintigraphy
8%
Coherence
8%
Treatment Effect
8%
Somatostatin Receptor
8%
Birdshot Chorioretinopathy
8%
Endophthalmitis
8%
QuantiFERON
8%
Erdheim-Chester Disease
8%
Moxifloxacin
8%
Allele
8%
Infliximab
8%
Macular Edema
8%
Disease Activity
8%
Randomized Clinical Trial
8%
